Rydx S&P S-Cp 600 Pure Grw

Veracyte Inc. CEO reports common stock disposition

Corcept Therapeutics Inc Executives Sean Maduck Sold $1.6 Million in Stocks

William Blair Analyst Maintains Buy Rating on TransMedics Group

Protagonist Therapeutics Sees Significant Revenue Growth with Janssen Collaboration

TransMedics Executives Sell $435,660 in Stock

InterDigital Director Sells Common Stock

TransMedics Group Inc. Official Disposes of Common Stock

Veracyte Director Evan Jones Sells Company Common Stock

William Blair Analyst Maintains Buy Rating on InterDigital

Veracyte Director Jens Holstein Disposes of Company Common Stock

Powell Industries Reports Record Profits, Sees Strong 2026 Outlook

Daikon Industries Q3 2026 Earnings Beat Expectations

Dycom Industries released FY2026 Q3 earnings on November 19 Pre-Market EST, actual revenue USD 1.452 B (forecast USD 1.408 B), actual EPS USD 3.6299 (forecast USD 3.2018)

Dycom Industries released FY2026 9 Months Earnings on November 19 Pre-Market EST, actual revenue USD 4.088 B, actual EPS USD 9.0499

Powell Industries released FY2025 annual earnings on November 18 After-Market EST, actual revenue USD 1.104 B (forecast USD 1.099 B), actual EPS USD 14.86 (forecast USD 14.39)

Powell Industries released FY2025 Q4 earnings on November 18 After-Market EST, actual revenue USD 297.98 M (forecast USD 292.85 M), actual EPS USD 4.2277 (forecast USD 3.76)

TransMedics CEO and President Acquires Common Stock

Powell Industries reports Q4 financial results

Savant Capital LLC Increases Stake in InterDigital

H.C. Wainwright Analyst Reiterates Buy Rating on Protagonist Therapeutics

Treasure Gbl

SMX Security Matters

Gulf Resources

Wheeler Real Estate

Irobot

Dreamland

Praxis Precision Medicines

DigitalBridge

Toro

ChargePoint

Russell Investments Group Ltd. increased its holdings in Dycom Industries by 16.5% in Q2. Analysts have given Dycom a consensus 'Buy' rating, with a target price of $371.25. Dycom's stock opened at $354.84, with a 52-week high of $364.40. The company reported strong quarterly earnings, beating estimates with $3.63 EPS and $1.45 billion revenue, up 14.2% year-over-year.

Market Beat

Russell Investments Group Ltd.

Dycom Industries

Russell Investments Group Ltd. Increases Stock Holdings in Dycom Industries, Inc. $DY

VCYT

Officer Febbo Phillip of Veracyte Inc surrendered 2,955 shares back to the company to cover option exercise costs and tax liabilities, as disclosed in a Form 4 filed with the SEC on December 4, 2025. The transaction was valued at $136,403, with shares priced at $46.16. Febbo's ending holdings are 89,486 shares directly.

Reuters

Veracyte

Officer Febbo Surrenders 2,955 Of Veracyte Inc [VCYT]

Veracyte Inc's Vice President, Jonathan Wygant, surrendered 1,325 shares at $46.16 each, valued at $61,162, to cover option exercise costs and/or tax liabilities. His remaining direct holdings are 37,420 shares.

VP Wygant Surrenders 1,325 Of Veracyte Inc [VCYT]

Veracyte Inc's Vice President, Annie McGuire, disclosed a Form 4 filing with the SEC, indicating a surrender of 3,052 shares and a planned sale of 1,422 shares, valued at $67,261, under a prearranged trading plan. The transaction was executed to cover option exercise costs and tax liabilities, leaving McGuire with 78,499 direct holdings.

VP McGuire Sells 1,422 ($67.3K) Of Veracyte Inc [VCYT]

Veracyte Inc's CEO, Marc Stapley, disclosed a stock transaction involving the sale of 7,668 shares for $361,075, as per a Form 4 filed with the SEC. The transaction was part of a prearranged trading plan (10b5-1). Additionally, 7,914 shares were surrendered to cover option exercise costs and tax liabilities. Stapley's direct holdings now total 318,603 shares.

CEO Stapley Sells 7,668 ($361.1K) Of Veracyte Inc [VCYT]

Officer John Leite of Veracyte Inc filed a Form 4 with the SEC, disclosing a surrender of 2,900 shares and a planned sale of 1,278 shares under a 10b5-1 trading plan. The transactions were executed to cover option exercise costs and tax liabilities, with ending holdings of 82,113 shares.

Officer Leite Sells 1,278 ($60.7K) Of Veracyte Inc [VCYT]

Rebecca Chambers, CFO of Veracyte Inc, disclosed a sale of 13,278 shares worth $621,955, executed under a prearranged trading plan. Additionally, 3,384 shares were surrendered to cover option exercise costs and tax liabilities. Her ending holdings are 109,496 shares. The transaction was filed with the SEC on December 4, 2025.

CFO Chambers Sells 13,278 ($622K) Of Veracyte Inc [VCYT]

Veracyte Inc.'s CEO, Marc Stapley, reported the disposal of common shares. The filing is available via EDGAR, the SEC's system. This AI-generated news brief is for informational purposes only and not financial advice. Veracyte Inc. is responsible for the original content.

Veracyte CEO Marc Stapley Reports Disposal of Common Shares

IDCC

InterDigital Inc. has declared a quarterly cash dividend of $0.70 per share on its common stock.

InterDigital Comm

InterDigital Inc. declares $0.70 per share quarterly cash dividend

CORT

Corcept Therapeutics Insider Sold Shares Worth $1,590,490, According to a Recent SEC Filing

marketscreener

Corcept Therap

Corcept Therapeutics Insider Sold Shares Worth $1,590,490, According to a Recent SEC Filing

Officer Sean Maduck of Corcept Therapeutics Inc sold 20,000 shares worth $1.6 million, as disclosed in a Form 4 filed with the SEC. The sale was part of a prearranged trading plan (10b5-1). Ending holdings are 117,896 shares. The Washington Service offers insider trading analysis and data services.

Officer Maduck Sells 20,000 ($1.6M) Of Corcept Therapeutics Inc [CORT]

Officer Lyon Joseph Douglas of Corcept Therapeutics Inc sold 5,000 shares for $397,632 as part of a prearranged trading plan. The transaction was disclosed in a Form 4 filed with the SEC. The officer also exercised options and surrendered shares to cover costs and tax liabilities, ending with 10,523 shares directly held.

Officer Lyon Sells 5,000 ($397.6K) Of Corcept Therapeutics Inc [CORT]

Corcept Therapeutics Inc's CFO, Mokari Atabak, surrendered 118 shares back to the company on December 2, 2025, to cover option exercise costs and tax liabilities. The shares were valued at $9,414, with a price of $79.78 per share. Mokari's direct holdings now total 14,559 shares.

CFO Mokari Surrenders 118 Of Corcept Therapeutics Inc [CORT]

Guyer William Officer of Corcept Therapeutics Inc [CORT] filed a Form 4/A on December 3, 2025 with the Securities and Exchange Commission disclosing the following changes in ownership:DateTransactionSharesPriceValue11/17/25Gift5,287$0.00N/A11/25/25Sale4,500$80.90$364,070Ending Holdings: 787 (0 - Direct, 787 - Indirect) For a free trial, or to learn more about our insider trading analysis and data services, please visit or contact us at (301) 913-5100 or send an email to info@washingtonservice.com.Founded in 1970, The Washington Service provides securities professionals with financial, economic and public policy research and data.

Officer Guyer Sells 4,500 ($364.1K) Of Corcept Therapeutics Inc [CORT]-Amended

Robb Gary Charles, an officer of Corcept Therapeutics Inc, surrendered 148 shares back to the company to cover option exercise costs and tax liabilities. The transaction was filed with the SEC on December 3, 2025, with the shares valued at $11,807. His ending holdings are 37,052 shares, split between direct and indirect ownership.